The FDA has approved Nuplazid (pimavanserin) for the treatment of hallucinations and delusions association with Parkinson’s disease psychosis. In 2014, the FDA designated Nuplazid as a Breakthrough Therapy for this condition.

Indications: Nuplazid is a non-dopaminergic, selective serotonin inverse agonist preferentially targeting receptors that are thought to play an important role in Parkinson’s disease psychosis.

Dosage/administration: Nuplazid is an oral medication taken once a day with a recommended dose of 34 mg (two 17 mg tablets).

Adverse reactions: The most common adverse reactions were peripheral edema, nausea, confusional state, hallucination, constipation, and gait disturbance.

Citation: US Food and Drug Administration. FDA approves ACADIA Pharmaceuticals’ NUPLAZID (pimavanserin)—The first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. FDA Web site. April 29, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm Accessed May 2, 2016.